Fundraising Fox

Longwall Venture Partners LLP

Venture capital

Harwell · Seed–Series A · 6 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

Longwall Venture Partners provides early-stage venture capital and company-building support for UK deeptech, helping turn scientific research into enduring global businesses. The firm emphasizes patient capital and technical fluency, recognizing that deep, emergent technology requires investors who understand the long journey from prototype to product and from first customer to category leader. Longwall works closely and deliberately with founders from day one, prioritizing customer engagement and avoiding over-engineering. Active since 2008, it positions itself as a long-term partner willing to back ambitious hard-science ideas that other investors underestimate.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series A
Check
$2M
HQ
Harwell, GB
Leads rounds
Leads
Instruments
Equity
Founded
2008
AUM
$88.9M
Tracked investments
14

Team · 6 people

from the firm's website & public directories

What they invest in

from 7 of 14 portfolio companies

Biotech ×6Deep Tech ×4Healthtech ×3Hardware ×2Medical Devices ×2Advanced Manufacturing ×1AI & Machine Learning ×1Digital Health ×1

Investments · 14 tracked

founders shown can be your intro path
Biofidelity Revolutionising genomic analysisbiofidelity.comin𝕏

Biofidelity develops genomic biomarker testing technologies—its Aspyre and Enspyre products—for cancer detection, treatment selection, and minimal residual disease monitoring.

BiotechHealthtechMedical Devices

Focus Sensorsfocus-sensors.com
Kinomicakinomica.com

Kinomica develops KScan, a phosphoproteomic diagnostic platform that analyzes which proteins and signaling pathways are activated to guide treatment selection for patients and support the discovery of new drug targets.

BiotechDeep TechDigital Health

Lettusgrowlettusgrow.comin
Lightcastlightcast.bioin

Lightcast develops Envisia, a next-generation platform for single-cell functional screening and analysis that enables researchers to study biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.

AI & Machine LearningBiotechDeep Tech

MFXmfx.bioin𝕏

MFX develops the Cyto Engine, an automated bioprocessing platform that accelerates development and manufacturing of engineered cells for cell and gene therapy.

BiotechDeep TechHealthtech

OrganOxorganox.comin

OrganOx develops organ preservation and transplantation technology used by research institutions to keep and treat organs, aimed at supporting transplantation and reducing the future need for transplants.

BiotechHealthtechMedical Devices

Oxford Space Systems - companyoxford.space

Enables lower launch costs and scalable capabilities for civil and defence space applications.

Oxfordbiooxfordbio.com
Oxfordpvoxfordpv.com
Oxsonicsoxsonics.com
Verdelinstrumentsverdelinstruments.comin

Verdel Instruments develops total correlation mass spectrometry (TOC-MS), a method using stored waveform ion radius modulation (SWIM) to generate MS/MS data for every analyte in a complex mixture.

BiotechDeep TechHardware

Waylandadditivewaylandadditive.comin

Wayland Additive develops metal additive manufacturing systems using its NeuBeam electron beam process, offered through its Calibur3 machine as an alternative to L-PBF and traditional eBeam systems.

Advanced ManufacturingHardwareNew Materials

Portfolio news

latest coverage across their companies

Principals & officers · per Companies House

what is this? ⓘ
Jane Elizabeth Burgoyne

LLP designated member · since 2017

David James Edmonds Denny

LLP designated member · since 2011

Matthew Gerard Winston Frohn

LLP designated member · since 2011

Ownership & control

David James Edmonds Denny25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Matthew Gerard Winston Frohn25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Jane Elizabeth Burgoyne25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership

Frequently asked questions

What stage does Longwall Venture Partners LLP invest at?
Longwall Venture Partners LLP invests at the Seed, Series A stages.
What is Longwall Venture Partners LLP's typical check size?
Longwall Venture Partners LLP typically writes checks of $2M.
What sectors does Longwall Venture Partners LLP focus on?
Longwall Venture Partners LLP focuses on Biotech, Deep Tech, Hardware, Healthtech, IoT, Medical Devices, New Materials, SaaS.
Where is Longwall Venture Partners LLP located?
Longwall Venture Partners LLP is headquartered in Harwell, GB.
Does Longwall Venture Partners LLP lead rounds?
Yes, Longwall Venture Partners LLP leads investment rounds.

Similar investors

Featured in lists